Results 161 to 170 of about 130,472 (328)

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Freedon study: Real‐life outcomes of cenobamate in different lines of treatment

Epilepsia, EarlyView.
Abstract Objectives Cenobamate is an antiseizure medication (ASM) with proven effectiveness in individuals with highly refractory epilepsy. This study investigated the effectiveness and tolerability of cenobamate in different treatment lines and a less refractory setting. Methods This was a multicenter, retrospective, observational study.
Vicente Villanueva, José María Serratosa, Alejandro Fernández‐Cabrera, Manuel Toledo, Beatriz González‐Giráldez, José C. Estevez, Juan Jesús Rodríguez Uranga, Maria Machio Castelló, Maria Dolores Castro‐Vilanova, Juan José Poza, Xiana Rodríguez‐Osorio, Kevin G. Hampel, Elena Fonseca, Francisco Javier López‐González, Mercedes Garcés, Laura Abraira, Jordi Ciurans, Daniel Campos‐Fernández, Estevo Santamarina, Juan María Sanchez‐Caro, Lucas Iacampo, Julia Renau, Miguel Ángel García‐Quesada, Carla Anciones, María Isabel Chamorro, Iratxe Maestro, Pablo Cabezudo, Raquel Calle, Jesús Macarron, Beatriz Cabezas, María Carrasco, María López, Marta Marín, Rosa Querol, Belén Baena, Vanessa García‐Morales, Samuel López‐Maza, Álvaro Juiz, Blanca Mercedes‐Alvarez, Carla Amarante, Ana del Villar, Ascensión Castillo, Marta Rubio‐Roy, Javier Martinez‐Poles, Asier Gómez‐Ibáñez, Beatriz Parejo‐Carbonell, Anabelén Martínez Garcia, Ignacio Carrera, Pablo Iriarte, Fátima Romero‐Aguilera, on behalf of the Pharmacological Therapy Working group of the Spanish Epilepsy Society and Freedon Group   +50 more
wiley   +1 more source

Structural basis for the allosteric regulation of the SbtA bicarbonate transporter by the P _II -like protein, SbtB, from Cyanobium sp. PCC7001

, 2019
Joe A. Kaczmarski, Nansook Hong, Bratati Mukherjee, Laura T. Wey, Loraine M. Rourke, Britta Förster, Thomas S. Peat, G. Dean Price, Colin J. Jackson   +8 more
openalex   +1 more source

Stiripentol: Unpublished results from the first phase 2 clinical trial in Lennox–Gastaut syndrome conducted in the early 1990s

Epilepsia, EarlyView.
Abstract Objective This study was undertaken to present the results of an exploratory phase 2 trial of stiripentol in Lennox–Gastaut syndrome (LGS). Methods This exploratory single‐blind, single‐arm, nonrandomized sequential‐period phase 2 study was conducted at four centers in France between January 1989 and August 1993.
Stéphane Auvin, Benjamin Serraz, Jérémie Lespinasse, Laurent Chancharme   +3 more
wiley   +1 more source

Cryo-EM reveals an extrahelical allosteric binding site at the M5 mAChR

Nature Communications
The M5 muscarinic acetylcholine receptor (M5 mAChR) represents a promising therapeutic target for neurological disorders. However, the high conservation of its orthosteric binding site poses significant challenges for drug development.
Wessel A. C. Burger, Jesse I. Mobbs, Bhavika Rana, Jinan Wang, Keya Joshi, Patrick R. Gentry, Mahmuda Yeasmin, Hariprasad Venugopal, Aaron M. Bender, Craig W. Lindsley, Yinglong Miao, Arthur Christopoulos, Celine Valant, David M. Thal   +13 more
doaj   +1 more source

Faculty Opinions recommendation of The HUS box is required for allosteric regulation of the Sec7 Arf-GEF.

, 2019
Andrew B. Goryachev
openalex   +2 more sources

Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome

Epilepsia, EarlyView.
Overview of the phase 3 trial evaluating soticlestat as adjunctive therapy in children and young adults with Dravet syndrome. Abstract Objective This study evaluated the efficacy, safety, and tolerability of soticlestat as adjunctive therapy in children and young adults with Dravet syndrome (DS).
Joseph Sullivan, Kette Valente, Vicente Villanueva, Adam Strzelczyk, Rima Nabbout, Eiji Nakagawa, Yuehua Zhang, Marta Zolnowska, Yasir Khan, Cheng Dong, Samuel Hsiao, Sarah I. Sheikh, Philipp von Rosenstiel, Mahnaz Asgharnejad, Venkatesha Murthy   +14 more
wiley   +1 more source

Identification of Regions of Rabbit Muscle Pyruvate Kinase Important for Allosteric Regulation by Phenylalanine, Detected by H/D Exchange Mass Spectrometry

, 2013
Charulata B. Prasannan, María T. Villar, Antonio Artigues, Aron W. Fenton   +3 more
openalex   +2 more sources

Mechanistic insights into the allosteric regulation of bacterial ADP-glucose pyrophosphorylases [PDF]

, 2017
Natalia Comino, Javier O. Cifuente, Alberto Marina, Ane Orrantia, Ander Eguskiza, Marcelo E. Guerin   +5 more
openalex   +1 more source

Probing allosteric regulations with coevolution-driven molecular simulations [PDF]

, 2021
Francesco Colizzi, Modesto Orozco
openalex   +1 more source